COVID-19 Causes 67% of Experts to use Decentralized Trials in Future, says GlobalData
Healthcare experts have noted that their number one primary concern amid the COVID-19 pandemic was the delay to initiation or inability to conduct clinical trials, according to a recent survey by GlobalData. The data and analytics company notes that at peak over 1,200 clinical trials experienced some level of delay due to the COVID-19 pandemic.
The survey, completed between June 4th-22th, found remote patient monitoring and shifting towards the use of decentralized clinical trials were the top two methods respondents are using to address disruptions. Out of 150 respondents, only 34% were already using decentralized clinical trials, most located in North America. Contract service providers were the biggest current adopters.
Furthermore, according to 67% of survey participants, COVID-19 is the reason they plan to use decentralized clinical trials in the future.
Read the full release and get more of the findings, here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
